Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RE1-silencing transcription factor (REST) network mRNAs comprise the set of messenger RNAs whose transcription is controlled by the REST protein, also known as the Neuron-Restrictive Silencer Factor (NRSF). REST acts as a master repressor by binding to the Repressor Element 1 (RE1) motif in the promoters of over 2,000 genes, many of which are essential for neuronal function, synaptic plasticity, and neurogenesis (Ooi & Wood, 2007, PubMed: 15685173). In healthy individuals, REST is highly expressed in non-neuronal cells to silence neuronal genes and is downregulated in mature neurons; however, its dysregulation is a hallmark of several pathologies. For example, the loss of REST in the aging brain is strongly linked to the progression of Alzheimer's disease and neurodegeneration, as REST normally provides neuroprotection against oxidative stress and amyloid-beta toxicity (Lu et al., 2014, PubMed: 24646994). Conversely, REST overexpression is observed in various cancers, where it can act as either an oncogene or a tumor suppressor depending on the cellular context (Negrini et al., 2013, PubMed: 22864569). Therapeutic targeting of this network typically involves small molecules or antisense oligonucleotides designed to modulate REST activity, thereby restoring the homeostatic balance of its downstream mRNAs to treat neurological disorders or malignancy.
Modulation of REST-mediated transcriptional repression through inhibition of REST protein activity or its recruitment of co-repressor complexes (e.g., HDACs, LSD1), thereby altering the expression levels of downstream network mRNAs (Soldati et al., 2012, PubMed: 22383400).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RE1-silencing transcription factor (REST) network mRNAs (REST network mRNAs).